publication venue for
- Rivaroxaban with or without aspirin for prevention of cardiovascular disease. 29:361-365. 2018
- Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2). 24:412-418. 2013
- Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. 21:336-344. 2010
- Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. 21:129-136. 2010
- Multidecade-long trends (1986–2005) in the utilization of coronary reperfusion and revascularization treatment strategies in patients hospitalized with acute myocardial infarction: a community-wide perspective. 20:71-80. 2009
- The role of platelets and platelet inhibition in acute myocardial infarction. 14:357-363. 2003
- Prolongation of the QT-corrected interval during dobutamine stress echocardiography: a marker for ischemia. 14:233-237. 2003
- Current developments in and future direction of coronary magnetic resonance angiography. 10:135-140. 1999
- The role of digitalis in the treatment of heart failure. 10:353-360. 1999
- The new heparins. 9:65-74. 1998
- Biologic rationale for the therapeutic role of specific antithrombins. 7:409-419. 1996
- Results of randomized clinical trials of magnesium - can a consensus be reached?. 7:341-347. 1996
- Magnetic resonance imaging of coronary arteries. 6:368-376. 1995
- Anticoagulation/platelet inhibition for atrial fibrillation. 6:129-136. 1995
- Calcium antagonists in the treatment of ischemic heart disease. 5:21-26. 1994
- Heparin and low-molecular weight heparins. 3:990-1002. 1992